<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The relatively low incidence of device-treated <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in patients with ischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> (ICM) who receive implantable cardioverter defibrillators (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e>) for primary prevention makes improved risk stratification of ICM patients a priority </plain></SENT>
<SENT sid="1" pm="."><plain>Although Cornell product (CP) ECG <z:hpo ids='HP_0001712'>left ventricular hypertrophy</z:hpo> (LVH) has been associated with increased mortality in hypertensive patients and population-based studies, whether CP LVH can improve risk stratification of high-risk ICM patients is unclear </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study is to examine if electrocardiographic LVH predicts mortality and incident <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> in patients with ICM </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: <z:hpo ids='HP_0000001'>All</z:hpo>-cause mortality was examined in 317 patients with ICM and a history of non-sustained <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT) who underwent electrophysiology testing </plain></SENT>
<SENT sid="4" pm="."><plain>Incident VT and <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) were assessed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> recipients (n = 186) </plain></SENT>
<SENT sid="5" pm="."><plain>ECG LVH was defined by CP criteria: [(R (aVL) + S (V3)) + 6 mm in women] × QRS duration &gt;2,440 mm ms </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: During 3 years of follow-up, mortality was 20% (64 of 317) and <z:hpo ids='HP_0011420'>death</z:hpo> or incident VT or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> occurred in 35% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> recipients </plain></SENT>
<SENT sid="7" pm="."><plain>CP LVH was associated with significantly greater 3-year mortality (28% vs 15%, p = 0.015) and 3-year mortality or incident VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> patients (48% vs 35%, p = 0.011) </plain></SENT>
<SENT sid="8" pm="."><plain>In Cox multivariate models, CP LVH was an independent predictor of mortality in <z:hpo ids='HP_0000001'>all</z:hpo> patients (hazard ratio (HR) 1.81, 95% confidence interval (CI) 1.11-2.97, p = 0.020) and of the composite endpoint of mortality or incident <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> patients (HR 1.82, 95% CI 1.12-3.00, p = 0.016) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: ECG LVH using CP criteria may enhance risk stratification in high-risk patients with ICM </plain></SENT>
</text></document>